Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avatrombopag in adults with refractory, relapsed, or ATG-ineligible aplastic anemia
jRCT2011260012Phase 3Recruiting
- Sponsor
- Sobi
- Start
- Sep 2026
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of avatrombopag in aplastic anemia, sponsored by Sobi. Primary endpoints: Hematological response at Week 26, Platelet response component and 2 more. Started Sep 2026; status: recruiting.
02
Drugs
avatrombopag
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on jRCT2011260012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011260012.